Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
Become a Member | Sign in
Home>News>This Article

Theorem and Gallus Announce an Exclusive Partnership

Published: Monday, August 13, 2012
Last Updated: Monday, August 13, 2012
Bookmark and Share
Partnership to help companies accelerate their research, development and manufacturing of biopharmaceuticals.

Theorem Clinical Research (Theorem) has entered an exclusive partnership with Gallus BioPharmaceuticals (Gallus).

In this partnership, Gallus will provide process development and clinical and commercial supply for mammalian cell-based biopharmaceutical products to Theorem’s customers.

In return, Theorem will offer contract research services to Gallus’ customers to increase both companies’ global reach and accelerate their customers’ products through the clinic to market.

According to an article by Outsourcing-Pharma writer Natalie Morrison, the current working relationship between sponsor companies and service providers is too lengthy and costly because it is based on ideas that are up to a century old.

Morrison adds that combining contract research organization (CRO) and contract development and manufacturing organization (CMO) activities, the development paradigm becomes much smoother and more efficient.

Gallus and Theorem agree with Morrison’s findings and their collaboration is aimed at addressing this issue by supporting the needs of their customers to outsource the research, development and ultimate commercial production of products more cost effectively and to accelerate the path to market.

“Our intent is to make the process as seamless as possible,” said Gallus President and CEO Mark Bamforth.

Theorem is one of the industry’s leading full-service, global CROs providing core clinical research and development services.

The company provides core CRO services for Phases I to IV, but with niche business units in the areas of clinical analytics, medical device and pharmaceutics.

Theorem Chief Executive Officer John Potthoff said that many of Theorem’s customers, especially those in Asia, need manufacturing assistance in the U.S. market.

According to Potthoff, Theorem’s partnership with Gallus will ensure that Theorem’s customers receive top-notch service and have access to everything they need to advance their trials and prepare for submission success with superior clinical and commercial supply.

Gallus is a world-class CMO, operating a commercially licensed manufacturing site in St. Louis.

With more than 25 years of experience in process development and a decade of commercial manufacturing, the company’s facilities are designed to support the development of early-phase processes through scale-up and full clinical and commercial production.

Bamforth said that Gallus’ mission is to meet the biopharmaceutical supply needs of customers through a premier manufacturing operation, leveraging the organization’s deep experience in development and manufacturing with an entrepreneurial, innovative, customer focus.

“With our new collaboration with Theorem, we’ll be able to expand our portfolio of high quality services to meet more of the comprehensive demands of our customers,” he said.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Solvent-free, Catalyst-free Peracetylation of Natural Products
In this study, a tunable microwave-assisted method for the solvent-free and catalyst-free peracetylation of natural products was developed.
Sonochemical Reactors
A critical analysis of the underlying mechanisms for intensification, available reactor configurations and overview of the different applications exploited successfully are presented.
Economical and Scalable Synthesis of 6-amino-2-cyanobenzothiazole
An economical and scalable synthesis of ACBT is presented, along with advantages for scale-up over previously reported routes.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos